| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.14.10.1569 |
| P698 | PubMed publication ID | 7918306 |
| P2093 | author name string | T Murakami | |
| G Vecchio | |||
| C R Sirtori | |||
| G Franceschini | |||
| G Gianfranceschi | |||
| F Pazzucconi | |||
| M Sirtori | |||
| M Cassinotti | |||
| A L D'Acquarica | |||
| P433 | issue | 10 | |
| P921 | main subject | familial combined hyperlipidemia | Q2242370 |
| P304 | page(s) | 1569-1575 | |
| P577 | publication date | 1994-10-01 | |
| P1433 | published in | Arteriosclerosis and thrombosis : a journal of vascular biology | Q27709770 |
| P1476 | title | Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern | |
| P478 | volume | 14 |
| Q73229430 | A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin |
| Q41445253 | Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors |
| Q34327226 | Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century |
| Q73369927 | Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia |
| Q46114213 | Did grandma give you heart disease? The new battle against coronary artery disease |
| Q30310112 | Effectiveness of multiple antilipidemic agents on Vertical Auto Profile II guided treatment of dyslipoproteinemia |
| Q44317936 | Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes |
| Q43833266 | Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial |
| Q50062211 | Influence of body variables in the development of metabolic syndrome-A long term follow-up study |
| Q33693960 | LDL particle size: an important drug target? |
| Q35005057 | N-3 fatty acids and diabetes |
| Q61781878 | Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses |
| Q49554117 | Pharmacological Intervention to Modulate HDL: What Do We Target? |
| Q77366640 | Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin |
| Q41348490 | Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease |
| Q34003407 | Preventing, stopping, or reversing coronary artery disease--triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: the need for recognition and treatment |
| Q34220548 | Prevention of a first myocardial infarction |
| Q41731956 | Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia |
| Q73691630 | Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia |
| Q34090712 | Statins do not decrease small, dense low-density lipoprotein |
| Q31729365 | The benefits of niacin in atherosclerosis |
| Q37705070 | Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel tri |
Search more.